|
1
|
Thai AA, Solomon BJ, Sequist LV, Gainor JF
and Heist RS: Lung cancer. Lancet. 398:535–554. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li Y, Yan B and He S: Advances and
challenges in the treatment of lung cancer. Biomed Pharmacother.
169:1158912023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wathoni N, Puluhulawa LE, Joni IM,
Muchtaridi M, Mohammed AFA, Elamin KM, Milanda T and Gozali D:
Monoclonal antibody as a targeting mediator for nanoparticle
targeted delivery system for lung cancer. Drug Deliv. 29:2959–2970.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Carter BW, Lichtenberger JP III,
Benveniste MK, de Groot PM, Wu CC, Erasmus JJ and Truong MT:
Revisions to the TNM staging of lung cancer: Rationale,
significance, and clinical application. Radiographics. 38:374–391.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Evison M and AstraZeneca UK Limited: The
current treatment landscape in the UK for stage III NSCLC. Br J
Cancer. 123:3–9. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Du X, Yang B, An Q, Assaraf YG, Cao X and
Xia J: Acquired resistance to third-generation EGFR-TKIs and
emerging next-generation EGFR inhibitors. Innovation (Camb).
2:1001032021.PubMed/NCBI
|
|
7
|
Cheng Y, He Y, Li W, Zhang HL, Zhou Q,
Wang B, Liu C, Walding A, Saggese M, Huang X, et al: Osimertinib
versus comparator EGFR TKI as first-line treatment for EGFR-mutated
advanced NSCLC: FLAURA China, A randomized study. Target Oncol.
16:165–176. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang Z, Cai G, Zhu J, Wang J and Zhang Y:
Treatment of advanced-stage non-small cell lung cancer: Current
progress and a glimpse into the future (Review). Mol Clin Oncol.
22:422025. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Aoki M, Ueda K, Umehara T, Kamimura GO,
Tokunaga T, Harada-Takeda A, Maeda K, Nagata T, Yokomakura N,
Kariatsumari K, et al: Targeted therapy followed by cytotoxic
chemotherapy in preoperative patients with locally advanced lung
adenocarcinoma. Anticancer Res. 40:2911–2916. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shukla AA, Podder S, Chaudry SR, Benn BS
and Kurman JS: Non-small cell lung cancer: Epidemiology, screening,
diagnosis, and treatment. AIMS Med Sci. 9:348–361. 2022. View Article : Google Scholar
|
|
11
|
Chen KN: The diagnosis and treatment of
lung cancer presented as ground-glass nodule. Gen Thorac Cardiovasc
Surg. 68:697–702. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tan AC, Teh YL, Lai GGY and Tan DSW: Third
generation EGFR TKI landscape for metastatic EGFR mutant non-small
cell lung cancer (NSCLC). Expert Rev Anticancer Ther. 19:431–435.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Villaruz LC, Burns TF, Ramfidis VS and
Socinski MA: Personalizing therapy in advanced non-small cell lung
cancer. Semin Respir Crit Care Med. 34:822–836. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Grant C and Nagasaka M: Neoadjuvant
EGFR-TKI therapy in non-small cell lung cancer. Cancer Treat Rev.
126:1027242024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sorin M, Huynh C, Rokah M, Dubé LR, Rayes
R, Ofiara L, Shieh B, Owen S, Fiset PO, et al: Neoadjuvant targeted
therapy in non-small cell lung cancer and its impact on surgical
outcomes. Ann Thorac Surg Short Rep. 1:102–106. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang K, Yi H, Lv Z, Jin D, Fu L and Mao Y:
Analysis of surgical complexity and short-term prognostic
indicators in NSCLC patients: Neoadjuvant targeted therapy versus
neoadjuvant chemoimmunotherapy. Ther Adv Med Oncol.
16:175883592412652142024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Reguart N and Remon J: Common EGFR-mutated
subgroups (Del19/L858R) in advanced non-small-cell lung cancer:
Chasing better outcomes with tyrosine kinase inhibitors. Future
Oncol. 11:1245–1257. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chaft JE, Shyr Y, Sepesi B and Forde PM:
Preoperative and postoperative systemic therapy for operable
non-small-cell lung cancer. J Clin Oncol. 40:546–555. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lu S, Wang Q, Zhang G, Dong X, Yang CT,
Song Y, Chang GC, Lu Y, Pan H, Chiu CH, et al: Efficacy of
Aumolertinib (HS-10296) in patients with advanced EGFR T790M+
NSCLC: Updated post-national medical products administration
approval results from the Apollo registrational trial. J Thorac
Oncol. 17:411–422. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu L, Zhong W, Li A, Qiu Z, Xie R, Shi H
and Lu S: Successful treatment of EGFR T790M-mutant non-small cell
lung cancer with almonertinib after osimertinib-induced
interstitial lung disease: A case report and literature review. Ann
Transl Med. 9:9502021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou C, Xie L, Liu W, Zhang L, Zhou S,
Wang L, Chen J, Li H, Zhao Y, Zhu B, et al: Absorption, metabolism,
excretion, and safety of [(14)C]almonertinib in healthy chinese
subjects. Ann Transl Med. 9:8672021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang JC, Camidge DR, Yang CT, Zhou J, Guo
R, Chiu CH, Chang GC, Shiah HS, Chen Y, Wang CC, et al: Safety,
efficacy, and pharmacokinetics of almonertinib (HS-10296) in
pretreated patients with EGFR-mutated advanced NSCLC: A
multicenter, open-label, phase 1 trial. J Thorac Oncol.
15:1907–1918. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Arbour KC and Riely GJ: Systemic therapy
for locally advanced and metastatic non-small cell lung cancer: A
review. JAMA. 322:764–774. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li K, Cao X, Ai B, Xiao H, Huang Q, Zhang
Z, Chu Q, Zhang L, Dai X and Liao Y: Salvage surgery following
downstaging of advanced non-small cell lung cancer by targeted
therapy. Thorac Cancer. 12:2161–2169. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fukuoka M, Wu YL, Thongprasert S,
Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu
DT, Saijo N, et al: Biomarker analyses and final overall survival
results from a phase III, randomized, open-label, first-line study
of gefitinib versus carboplatin/paclitaxel in clinically selected
patients with advanced non-small-cell lung cancer in Asia (IPASS).
J Clin Oncol. 29:2866–2874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shang Z and Li J: Comparison of clinical
efficacy between chrono-chemotherapy and conventional chemotherapy
in patients with non-small cell lung cancer. Am J Cancer Res.
13:4277–4287. 2023.PubMed/NCBI
|
|
27
|
Randon G, Lonardi S, Fassan M, Palermo F,
Tamberi S, Giommoni E, Ceccon C, Di Donato S, Fornaro L, Brunetti
O, et al: Ramucirumab plus paclitaxel as switch maintenance versus
continuation of first-line oxaliplatin-based chemotherapy in
patients with advanced HER2-negative gastric or gastro-oesophageal
junction cancer (ARMANI): A randomised, open-label, multicentre,
phase 3 trial. Lancet Oncol. 25:1539–1550. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Song W, Di S, Liu J, Fan B, Zhao J, Zhou
S, Chen S, Dong H, Yue C and Gong T: Salvage surgery for advanced
non-small cell lung cancer after targeted therapy: A case series.
Thorac Cancer. 11:1061–1067. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lengel HB, Zheng J, Tan KS, Liu CC, Park
BJ, Rocco G, Adusumilli PS, Molena D, Yu HA, Riely GJ, et al:
Clinicopathologic outcomes of preoperative targeted therapy in
patients with clinical stage I to III non-small cell lung cancer. J
Thorac Cardiovasc Surg. 165:1682–1693. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bian D, Ji S, Liu Y, Huang Z, Jiang L, Liu
M, Bao X, Yang J, Zhou Y, Hu J, et al: Neoadjuvant Aumolertinib for
unresectable stage III EGFR-mutant non-small cell lung cancer: A
single-arm phase II trial. Nat Commun. 16:31432025. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bian D, Sun L, Hu J, Duan L, Xia H, Zhu X,
Sun F, Zhang L, Yu H, Xiong Y, et al: Neoadjuvant Afatinib for
stage III EGFR-mutant non-small cell lung cancer: A phase II study.
Nat Commun. 14:46552023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lu S, Dong X, Jian H, Chen J, Chen G, Sun
Y, Ji Y, Wang Z, Shi J, Lu J, et al: Aeneas: A randomized phase III
trial of aumolertinib versus gefitinib as first-line therapy for
locally advanced or metastatic non-small-cell lung cancer with EGFR
exon 19 deletion or L858R mutations. J Clin Oncol. 40:3162–3171.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yan CY, Zhao ML, Wei YN and Zhao XH:
Mechanisms of drug resistance in breast cancer liver metastases:
Dilemmas and opportunities. Mol Ther Oncolytics. 28:212–229. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang K and Liu H: Identification of
drug-resistant individual cells within tumors by semi-supervised
transfer learning from bulk to single-cell transcriptome. Commun
Biol. 8:5302025. View Article : Google Scholar : PubMed/NCBI
|
